Skip to main content
. 2016 May 6;7(24):36255–36265. doi: 10.18632/oncotarget.9199

Figure 1. High TAZ expression is a prognostic indicator of poor survival in glioblastoma patients.

Figure 1

(A) Kaplan-Meier analysis of progression-free survival for the TCGA database with the log rank test P value was indicated. Cutoff:400-1094.1: raw p: 4.4e-5 (bonf: 0.021) (B) Kaplan-Meier analysis of progression-free survival for the Frence database with the log rank test P value indicated. Cutoff: 151-1028.0: raw p: 1.4e-11 (bonf: 3.6e-09) (C) Box plot of TAZ expression levels from non-tumor, GBM and recurrent GBM patients was shown. (D) Box plot of TAZ expression levels in the normal, stage 1 to 3 and GBM tumors. (E) Box plot of TAZ expression levels in the stage 2 and 4 tumors. (F) Western blot assay of TAZ expression in GBM cell lines and different tissues was performed. All data are shown as the mean ± SD, *p < 0.05, **p < 0.01. All p values are based on analysis control versus treatment.